loading
Halozyme Therapeutics Inc stock is traded at $55.20, with a volume of 841.24K. It is down -1.58% in the last 24 hours and down -9.81% over the past month. Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$56.07
Open:
$55.69
24h Volume:
841.24K
Relative Volume:
0.40
Market Cap:
$6.80B
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
18.28
EPS:
3.02
Net Cash Flow:
$392.71M
1W Performance:
+1.18%
1M Performance:
-9.81%
6M Performance:
+13.57%
1Y Performance:
+24.60%
1-Day Range:
Value
$54.49
$56.32
1-Week Range:
Value
$53.76
$56.39
52-Week Range:
Value
$42.01
$70.50

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Name
Name
Halozyme Therapeutics Inc
Name
Phone
(858) 794-8889
Name
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Name
Employee
350
Name
Twitter
@halozymeinc
Name
Next Earnings Date
2025-02-18
Name
Latest SEC Filings
Name
HALO's Discussions on Twitter

Compare HALO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
HALO
Halozyme Therapeutics Inc
55.17 6.71B 947.36M 392.47M 392.71M 3.02
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.21 25.76B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
444.67 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.40 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
83.43 6.44B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
496.42 65.13B 14.09B 4.50B 2.96B 39.28

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

Date Action Analyst Rating Change
May-14-25 Downgrade Morgan Stanley Overweight → Equal-Weight
May-13-25 Downgrade Leerink Partners Market Perform → Underperform
Oct-07-24 Downgrade Wells Fargo Overweight → Equal Weight
Sep-19-24 Downgrade JP Morgan Overweight → Neutral
Jun-07-24 Downgrade Piper Sandler Overweight → Neutral
Feb-29-24 Initiated TD Cowen Outperform
Jul-24-23 Downgrade Goldman Buy → Neutral
Jul-24-23 Initiated H.C. Wainwright Buy
May-10-23 Upgrade Piper Sandler Neutral → Overweight
Mar-27-23 Resumed Berenberg Buy
Mar-16-23 Downgrade SVB Securities Outperform → Market Perform
Dec-21-22 Resumed Morgan Stanley Overweight
Nov-28-22 Initiated Wells Fargo Overweight
Sep-09-22 Initiated Morgan Stanley Overweight
May-23-22 Initiated SVB Leerink Outperform
Jun-14-21 Initiated Evercore ISI Outperform
May-17-21 Initiated SVB Leerink Outperform
May-11-21 Downgrade Piper Sandler Overweight → Neutral
Jan-21-21 Reiterated The Benchmark Company Buy
Dec-17-20 Initiated Berenberg Buy
Sep-14-20 Resumed JP Morgan Overweight
Jul-01-20 Initiated The Benchmark Company Buy
Feb-05-20 Upgrade Piper Sandler Neutral → Overweight
Jan-09-20 Upgrade BMO Capital Markets Market Perform → Outperform
Jan-08-20 Initiated Goldman Buy
Nov-05-19 Upgrade Barclays Underweight → Equal Weight
Oct-19-18 Resumed Piper Jaffray Neutral
May-11-18 Downgrade Barclays Equal Weight → Underweight
Jan-24-18 Initiated Goldman Neutral
Oct-16-17 Reiterated Piper Jaffray Overweight
Jan-06-17 Downgrade Citigroup Buy → Neutral
Nov-03-16 Initiated Deutsche Bank Buy
Dec-04-15 Initiated Wells Fargo Outperform
Nov-18-15 Initiated Citigroup Buy
Sep-22-15 Initiated Barclays Overweight
Jun-22-15 Reiterated JP Morgan Overweight
Mar-03-15 Reiterated UBS Buy
Feb-18-15 Reiterated MLV & Co Buy
Jan-08-15 Reiterated MLV & Co Buy
View All

Halozyme Therapeutics Inc Stock (HALO) Latest News

pulisher
10:02 AM

(HALO) Investment Report - news.stocktradersdaily.com

10:02 AM
pulisher
May 31, 2025

H.C. Wainwright Reiterates Buy on Halozyme (HALO), Maintains Price Target - MSN

May 31, 2025
pulisher
May 30, 2025

Halozyme to Participate at Upcoming Investor Conferences - Kilgore News Herald

May 30, 2025
pulisher
May 30, 2025

Halozyme Therapeutics (NASDAQ:HALO) Receives “Buy” Rating from HC Wainwright - Defense World

May 30, 2025
pulisher
May 29, 2025

Halozyme Therapeutics (HALO): HC Wainwright & Co. Reiterates Buy Rating | HALO Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications - Longview News-Journal

May 29, 2025
pulisher
May 29, 2025

Halozyme stock holds Buy rating, $72 target from H.C. Wainwright By Investing.com - Investing.com UK

May 29, 2025
pulisher
May 28, 2025

Halozyme to Participate at Upcoming Investor Conferences | HALO Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Halozyme CEO Sets Two Major Healthcare Conference Appearances: Goldman Sachs and Benchmark - Stock Titan

May 28, 2025
pulisher
May 28, 2025

3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO) - sharewise

May 28, 2025
pulisher
May 28, 2025

Bristol-Myers wins EU nod for Opdivo injectable developed with Halozyme - MSN

May 28, 2025
pulisher
May 28, 2025

Bristol Myers Squibb, Halozyme Get EC Approval for Subcutaneous Formulation of Opdivo - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Implied Volatility Surging for Halozyme Therapeutics Stock Options - TradingView

May 28, 2025
pulisher
May 28, 2025

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Halozyme Says Bristol-Myers Squibb Gets EC Approval For Opdivo SC Developed With Halozyme's ENHANZE - Nasdaq

May 28, 2025
pulisher
May 28, 2025

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications | HALO Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

High Growth Tech Stocks To Watch In The US May 2025 - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

New Strong Buy Stocks for May 28th - The Globe and Mail

May 28, 2025
pulisher
May 18, 2025

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of “Hold” by Brokerages - Defense World

May 18, 2025
pulisher
May 16, 2025

J&J, Halozyme cut at Leerink on price control risk for combo products - MSN

May 16, 2025
pulisher
May 16, 2025

Halozyme Therapeutics (NASDAQ:HALO) Cut to “Strong Sell” at Leerink Partnrs - Defense World

May 16, 2025
pulisher
May 15, 2025

Halozyme downgraded at Morgan Stanley on price control risk - MSN

May 15, 2025
pulisher
May 15, 2025

Morgan Stanley Downgrades Halozyme Therapeutics (BIT:1HALO) - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Zacks.com featured highlights Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Morgan Stanley Downgrades Halozyme Therapeutics (LSE:0J2O) - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Leerink Partners Downgrades Halozyme Therapeutics (LSE:0J2O) - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Leerink Partners Downgrades Halozyme Therapeutics (NASDAQ:HALO) to Underperform - Defense World

May 15, 2025
pulisher
May 14, 2025

Halozyme (HALO) Downgraded by Morgan Stanley Amid Pricing Concer - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Leerink Partners Downgrades Halozyme Therapeutics (BMV:HALO) - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Halozyme Therapeutics (HALO) Downgraded by Morgan Stanley | HALO Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Halozyme, J&J slide as analyst cuts rating on CMS draft guidance - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Halozyme (HALO) Downgraded Amid Medicare Price Negotiation Conce - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Halozyme stock downgraded at Morgan Stanley (HALO:NASDAQ) - Seeking Alpha

May 14, 2025
pulisher
May 14, 2025

Halozyme Therapeutics downgraded by Morgan Stanley with a new price target - Quantisnow

May 14, 2025
pulisher
May 14, 2025

Why Halozyme Therapeutics, Inc. (HALO) Declined on Tuesday - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Halozyme stock holds $78 target despite Medicare concerns By Investing.com - Investing.com Canada

May 14, 2025
pulisher
May 14, 2025

Halozyme (HALO) Downgraded by Morgan Stanley Amid Pricing Concerns | HALO Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Halozyme stock holds $78 target despite Medicare concerns - Investing.com

May 14, 2025
pulisher
May 14, 2025

Morgan Stanley cuts Halozyme stock rating, lowers target By Investing.com - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) - MSN

May 14, 2025
pulisher
May 13, 2025

Halozyme at BofA Securities Conference: Strategic Growth Insights By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

Transcript : Halozyme Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 04 - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Evercore ISI maintains Outperform on Halozyme amid CMS draft By Investing.com - Investing.com Canada

May 13, 2025
pulisher
May 13, 2025

Halozyme at BofA Securities Conference: Strategic Growth Insights - Investing.com Australia

May 13, 2025
pulisher
May 13, 2025

Halozyme stock rating cut to Underperform at Leerink Partners By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News - Investor's Business Daily

May 13, 2025
pulisher
May 13, 2025

Evercore ISI maintains Outperform on Halozyme amid CMS draft - Investing.com

May 13, 2025
pulisher
May 13, 2025

Halozyme Shares Fall After Leerink Partners Downgrade - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Crude Oil Gains 3%; US Inflation Eases In April - Benzinga

May 13, 2025
pulisher
May 13, 2025

Halozyme Therapeutics (HALO) Downgraded Amid Medicare Negotiatio - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Halozyme (HALO) Stock Downgraded Amid Concerns Over CMS Guidance - GuruFocus

May 13, 2025

Halozyme Therapeutics Inc Stock (HALO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Halozyme Therapeutics Inc Stock (HALO) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Henderson Jeffrey William
Director
Apr 01 '25
Sale
64.05
503
32,217
33,108
Henderson Jeffrey William
Director
Mar 03 '25
Sale
58.69
5,000
293,458
33,611
LaBarre Michael J.
SVP, CHIEF TECHNICAL OFFICER
Feb 26 '25
Sale
58.12
10,000
581,244
175,453
LaBarre Michael J.
SVP, CHIEF TECHNICAL OFFICER
Feb 25 '25
Sale
58.05
10,000
580,534
185,453
LaBarre Michael J.
SVP, CHIEF TECHNICAL OFFICER
Feb 27 '25
Sale
58.28
1,697
98,902
173,756
$1.0846
price down icon 1.76%
$29.97
price down icon 0.70%
$577.79
price up icon 0.89%
$306.27
price up icon 0.67%
$4.47
price down icon 2.22%
$489.50
price down icon 0.11%
Cap:     |  Volume (24h):